← Leaderboards
Jason Stubbs
University Of Kansas Medical Center
$4,327,124
Attributed
$4,911,703
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $977K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,911,703 · 6
By mechanism
R01$3,516,215 · 2
K08$757,080 · 1
R21$421,068 · 1
R03$151,000 · 1
M01$66,340 · 1
Top collaborators
- Peter S Rowe2 shared
Others in their field
Top investigators on “Chronic Kidney Failure”
- John M Lachin · George Washington University$122,970,601
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$51,947,333
- Harold I Feldman · University Of Pennsylvania$48,933,882
- Jonathan Himmelfarb · Maine Medical Center$46,985,168
- Lisa P Jacobson · Johns Hopkins University$45,397,923
Research focus
Chronic Kidney FailureKidney DiseasesPreventDisease ProgressionMetabolismEnd Stage Renal FailureProductionInorganic PhosphateMouse ModelHormonesRenal FunctionInjuryFibroblast Growth Factor 23MineralsKidneyEquilibriumNephronsIn VitroPathway InteractionsPhenotypeExhibitsEventExcretory FunctionFunctional Disorder
Grant awards (18)
Preventing vascular calcification in kidney disease$591,857
R01 · FY2025 · HL
Preventing vascular calcification in kidney disease$577,302
R01 · FY2024 · HL
Impact of Phosphaturia on Renal Osteopontin Production and PKD Progression$399,670
R01 · FY2024 · DK · contact PI
Impact of Phosphaturia on Renal Osteopontin Production and PKD Progression$417,781
R01 · FY2023 · DK · contact PI
Impact of Phosphaturia on Renal Osteopontin Production and PKD Progression$413,590
R01 · FY2022 · DK · contact PI
Impact of Phosphaturia on Renal Osteopontin Production and PKD Progression$416,015
R01 · FY2021 · DK · contact PI
Impact of Phosphaturia on Renal Osteopontin Production and PKD Progression$350,000
R01 · FY2020 · DK · contact PI
Impact of Phosphaturia on Renal Osteopontin Production and PKD Progression$350,000
R01 · FY2019 · DK · contact PI
Randomized, Controlled Pilot Study of Rifaximin Therapy in Chronic Kidney Disease$229,818
R21 · FY2017 · DK · contact PI
Randomized, Controlled Pilot Study of Rifaximin Therapy in Chronic Kidney Disease$191,250
R21 · FY2016 · DK · contact PI
Impact of Endotoxin on Fibroblast Growth Factor 23 Production by Osteocytes$75,500
R03 · FY2015 · DK · contact PI
Exploring the interrelationships of mineral metabolism pathways in kidney disease$151,416
K08 · FY2014 · DK · contact PI
Impact of Endotoxin on Fibroblast Growth Factor 23 Production by Osteocytes$75,500
R03 · FY2014 · DK · contact PI
Exploring the interrelationships of mineral metabolism pathways in kidney disease$151,416
K08 · FY2013 · DK · contact PI
Exploring the interrelationships of mineral metabolism pathways in kidney disease$151,416
K08 · FY2012 · DK · contact PI
Exploring the interrelationships of mineral metabolism pathways in kidney disease$151,416
K08 · FY2011 · DK · contact PI
Exploring the interrelationships of mineral metabolism pathways in kidney disease$151,416
K08 · FY2010 · DK · contact PI
CLINICAL TRIAL: EXTRARENAL 1-ALPHA-HYDROXYLASE IN END-STAGE RENAL DISEASE$66,340
M01 · FY2009 · RR · contact PI